Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
IBRX 
Immunitybio Inc (IBRX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/16/2025: IBRX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $10.4
1 Year Target Price $10.4
| 3 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -80.39% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/16/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.13B USD | Price to earnings Ratio - | 1Y Target Price 10.4 |
Price to earnings Ratio - | 1Y Target Price 10.4 | ||
Volume (30-day avg) 5 | Beta -0.06 | 52 Weeks Range 1.83 - 4.27 | Updated Date 12/17/2025 |
52 Weeks Range 1.83 - 4.27 | Updated Date 12/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.41 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -173.51% |
Management Effectiveness
Return on Assets (TTM) -36.89% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 2471059697 | Price to Sales(TTM) 25.77 |
Enterprise Value 2471059697 | Price to Sales(TTM) 25.77 | ||
Enterprise Value to Revenue 29.93 | Enterprise Value to EBITDA -8.99 | Shares Outstanding 984965179 | Shares Floating 336375458 |
Shares Outstanding 984965179 | Shares Floating 336375458 | ||
Percent Insiders 66.41 | Percent Institutions 14.82 |
About Immunitybio Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2015-07-28 | President, CEO & Director Mr. Richard Gerald Adcock | ||
Sector Healthcare | Industry Biotechnology | Full time employees 673 | Website https://immunitybio.com |
Full time employees 673 | Website https://immunitybio.com | ||
ImmunityBio, Inc., a commercial stage biotechnology company, develops next-generation therapies that bolster the natural immune systems to defeat cancers and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead biologic product candidate includes Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute; Serum Institute of India Private Limited; and BeiGene, Ltd. ImmunityBio, Inc. is based in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.